External validation of the MRI-DRAGON score: early prediction of stroke outcome after intravenous thrombolysis

PLoS One. 2014 Jun 4;9(6):e99164. doi: 10.1371/journal.pone.0099164. eCollection 2014.

Abstract

Background and purpose: The aim of our study was to validate in an independent cohort the MRI-DRAGON score, an adaptation of the (CT-) DRAGON score to predict 3-month outcome in acute ischemic stroke patients undergoing MRI before intravenous thrombolysis (IV-tPA).

Methods: We reviewed consecutive (2009-2013) anterior circulation stroke patients treated within 4.5 hours by IV-tPA in the Lille stroke unit (France), where MRI is the first-line pretherapeutic work-up. We assessed the discrimination and calibration of the MRI-DRAGON score to predict poor 3-month outcome, defined as modified Rankin Score >2, using c-statistic and the Hosmer-Lemeshow test, respectively.

Results: We included 230 patients (mean ±SD age 70.4±16.0 years, median [IQR] baseline NIHSS 8 [5]-[14]; poor outcome in 78(34%) patients). The c-statistic was 0.81 (95%CI 0.75-0.87), and the Hosmer-Lemeshow test was not significant (p = 0.54).

Conclusions: The MRI-DRAGON score showed good prognostic performance in the external validation cohort. It could therefore be used to inform the patient's relatives about long-term prognosis and help to identify poor responders to IV-tPA alone, who may be candidates for additional therapeutic strategies, if they are otherwise eligible for such procedures based on the institutional criteria.

Publication types

  • Validation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Injections, Intravenous
  • Magnetic Resonance Imaging
  • Male
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Stroke / diagnosis*
  • Stroke / drug therapy*
  • Thrombolytic Therapy*

Substances

  • Fibrinolytic Agents

Grants and funding

The authors have no support or funding to report.